MétaCan
Menu
Back to cohort
Record W4299655517 · doi:10.1002/hep.28909

Late‐breaking abstracts

2016· article· en· W4299655517 on OpenAlexfundno aff

Bibliographic record

VenueHepatology · 2016
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicDiverse Scientific and Economic Studies
Canadian institutionsnot available
FundersGenentechTokyo Medical and Dental UniversityGrifolsHokkaido UniversityUniversity of TokyoInstitut National de la Santé et de la Recherche MédicaleUniversity of California MercedKanazawa UniversityZafgenIonis PharmaceuticalsKineMedBaxaltaInstitute of GeneticsAstraZenecaClovis OncologyCSL BehringNagoya City UniversityArrowhead PharmaceuticalsCOPD FoundationAlnylam PharmaceuticalsWashington University in St. LouisCalifornia Polytechnic State University, San Luis ObispoNara Medical UniversityStyrelsen för Internationellt UtvecklingssamarbeteDaiichi Sankyo EuropeGilead SciencesCelgene
KeywordsHepatologyMedicineInternal medicineLiver transplantationGastroenterologyLiver diseaseTransplantation

Abstract

fetched live from OpenAlex

Background: Cenicriviroc (CVC), an oral chemokine receptor CCR2/5 antagonist, has potent anti-inflammatory and antifibrotic activity in animal models of acute and chronic liver diseases. Its efficacy and safety as a treatment for non-alcoholic steatohepatitis (NASH) and liver fibrosis are being evaluated in adults at increased risk of progression to cirrhosis (CEN-TAUR; NCT02217475). Methods: Phase 2b, randomized, double-blind, placebo-controlled, ongoing 2-year multinational study; primary analysis at Year 1. Subjects with histologically defined NASH, a non-alcoholic fatty liver disease activity score (NAS) 4, liver fibrosis (stages 1-3 NASH CRN), and diabetes or metabolic syndrome (MetS) were randomized to CVC 150 mg QD or placebo. NAS, resolution of steatohepatitis, and fibrosis stage were assessed on Year 1 liver biopsies. Markers of systemic inflammation, treatment-emergent adverse events (TEAEs), and laboratory abnormalities were evaluated. Results: 289 subjects were randomized: 53% female; 52% diabetes; 72% MetS; 74% NAS 5; 67% fibrosis stage 2-3. Mean BMI (SD) was 34 kg/m 2 (6.5). A similar proportion in each group achieved the NAS and resolution of steatohepatitis endpoints (Table ). Improvement in fibrosis by 1 stage and no worsening of steatohepatitis was obtained in significantly more CVC-treated subjects than placebo overall (p=0.023) and in subgroups with histologically advanced disease char-acteristics. Improvement in fibrosis by 2 stages was observed in 11 subjects (8 CVC; 3 placebo). Seven subjects progressed to cirrhosis (2 CVC; 5 placebo). IL-6, hs-CRP, and fibrinogen levels were significantly decreased with CVC vs. placebo. Drug-related, clinical TEAEs of Grade 2 severity occurring in 2% of subjects were fatigue (2.8%) and diarrhea (2.1%) for CVC; headache (3.5%) for placebo. There were no differences in laboratory abnormalities or premature discontinuations between CVC and placebo. Conclusions: In the ITT population, CVC was well tolerated and resulted in twice as many subjects achieving 1 stage improvement in fibrosis and no worsening of steatohepatitis vs. placebo, after only 1 year of treatment. Importantly, greater treatment benefits were observed in subjects with higher disease activity and stage.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesInsufficient payload (model declined to judge)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.810
Threshold uncertainty score0.992

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0090.063

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.050
GPT teacher head0.211
Teacher spread0.162 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueHepatologySame topicDiverse Scientific and Economic StudiesFrench-language works237,207